Prosecution Insights
Last updated: November 04, 2026
Application No. 17/975,820

INCREASED HUMAN LIFE SPAN AND HEALTH SPAN THROUGH TRANSCRANIAL ELECTROMAGNETIC TREATMENT

Non-Final OA §102§103
Filed
Oct 28, 2022
Priority
Mar 11, 2013 — provisional 61/776,097 +5 more
Examiner
COX, THADDEUS B
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Neuroem Therapeutics Inc.
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
914 granted / 1186 resolved
+7.1% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
49 currently pending
Career history
1238
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1186 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01 September 2026 has been entered. Claims 10-14, 17, and 19-28 are currently under consideration. The Office acknowledges the amendments to claim 10, as well as the cancellation of claims 15, 16, and 18, and the addition of new claims 19-28. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent. Claims 10, 20, 21, and 28 are rejected under pre-AIA 35 U.S.C. 102(a)(1) as being anticipated by Arendash et al. (U.S. Pub. No. 2014/0257017 A1; hereinafter known as “Arendash”). Regarding claim 10, Arendash discloses a method capable of increasing human life span (longevity) via electromagnetic treatment (Abstract; [0002]-[0003]; preventing neurodegenerative disease), the method comprising: positioning an array of electromagnetic emitters proximal to a subject (Fig. 3; [0035]-[0036]); generating, by an electromagnetic wave generator, electromagnetic waves having a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100% ([0037]); applying the electromagnetic waves to the subject through the electromagnetic emitters to provide an increase of the life span of the subject ([0038]), and treating the subject for at least one age-related disease selected from: dementia, cardiovascular disease, cancer, AIDS, traumatic brain injury, chronic traumatic encephalopathy, post-operative cognitive dysfunction, cognitive impairment after anesthesia, Rheumatoid Arthritis, bacterial or viral infections, Multiple Sclerosis, arterial hypertension, autoimmune diseases, depression, anxiety, cognitive impairment in depression, allergy, asthma, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, osteoarthritis, atherosclerosis, diabetes, COPD, chronic kidney disease, metabolic syndrome, neurologic disorders, or Parkinson's disease ([0039]). The examiner notes that the recited predetermined set of parameters does not have to include each of the recited frequency, SAR, pulse repetition rate, and duty cycle. Indeed, the claim recites “a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100%.” Thus, while Arendash does not teach all four of these recited parameters, it does teach at least the recited frequency and therefore anticipates the claim as-written. To the extent that Luttrull could also be an anticipatory reference, it has been maintained herein as an obviousness-type reference (as seen infra) to demonstrate that the claim would still be rejected even if it recited “and a duty cycle.” Regarding claim 20, Arendash discloses that the electromagnetic waves are generated by peripheral electromagnetic treatment (PEMT) (Fig. 3; [0035]-[0037]). Regarding claim 21, Arendash discloses a method capable of increasing human life span (longevity) via electromagnetic treatment (Abstract; [0002]-[0003]; preventing neurodegenerative disease), the method comprising: positioning an array of electromagnetic emitters proximal to a subject (Fig. 3; [0035]-[0036]); generating, by an electromagnetic wave generator, electromagnetic waves having a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100% ([0037]); applying the electromagnetic waves to the subject through the electromagnetic emitters to provide an increase of the life span of the subject ([0038]), and treating the subject for at least one age-related disease selected from: all forms of dementia, all forms of cardiovascular disease, all forms of cancer, AIDS, traumatic brain injury, chronic traumatic encephalopathy, post-operative cognitive dysfunction, cognitive impairment after anesthesia, Rheumatoid Arthritis, bacterial or viral infections, Multiple Sclerosis, arterial hypertension, autoimmune diseases, all forms of depression and anxiety, cognitive impairment in depression, allergy, asthma, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, osteoarthritis, atherosclerosis, diabetes, COPD, chronic kidney disease, or metabolic syndrome ([0039]). The examiner again notes that the recited predetermined set of parameters does not have to include each of the recited frequency, SAR, pulse repetition rate, and duty cycle. Indeed, the claim recites “a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100%.” Thus, while Arendash does not teach all four of these recited parameters, it does teach at least the recited frequency and therefore anticipates the claim as-written. To the extent that Luttrull could also be an anticipatory reference, it has been maintained herein as an obviousness-type reference (as seen infra) to demonstrate that the claim would still be rejected even if it recited “and a duty cycle.” Regarding claim 28, Arendash discloses that the electromagnetic waves are generated by peripheral electromagnetic treatment (PEMT) (Fig. 3; [0035]-[0037]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 10-14, 17, 19, and 21-27 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Luttrull et al. (U.S. Pub. No. 2020/0360709 A1; hereinafter known as “Luttrull”), in view of Arendash et al. (U.S. Pub. No. 2016/0106997 A1; hereinafter known as “Arendash ‘997”). Regarding claim 10, Luttrull discloses a method capable of increasing human life span (longevity) via electromagnetic treatment (Abstract; preventing neurodegenerative disease), the method comprising: positioning an array of electromagnetic emitters 124 proximal to a subject (Figs. 40, 41; [0200]-[0201]); generating, by an electromagnetic wave generator 132, electromagnetic waves having a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100% ([0202]-[0205]); applying the electromagnetic waves to the subject through the electromagnetic emitters to provide an increase of the life span of the subject ([0205]-[0206]), and treating the subject for at least one age-related disease selected from: dementia, cardiovascular disease, cancer, AIDS, traumatic brain injury, chronic traumatic encephalopathy, post-operative cognitive dysfunction, cognitive impairment after anesthesia, Rheumatoid Arthritis, bacterial or viral infections, Multiple Sclerosis, arterial hypertension, autoimmune diseases, depression, anxiety, cognitive impairment in depression, allergy, asthma, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, osteoarthritis, atherosclerosis, diabetes, COPD, chronic kidney disease, metabolic syndrome, neurologic disorders, or Parkinson's disease ([0003]; [0059]; [0106]-[0107]; [0195]-[0196]; [0198]; [0290]; [0293]). Luttrull fails to expressly disclose an average SAR of 2.1 to 16 W/kg. Luttrull arguably renders this obvious, in light of its disclosure of 2.0 W/kg, as a prima facie case of obviousness can exist where the claimed ranges do not overlap with the prior art but are merely close. See MPEP 2144.05(I). However, for sake of completeness, Arendash ‘997 discloses a similar method (Abstract) that provides electromagnetic waves with a SAR of up to about 8 W/kg in order to enhance cognition and treat the underlying neurological disorder (Abstract; [0016]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Luttrull with the SAR taught by Arendash ‘997 in order to enhance cognition and treat the underlying neurological disorder. Regarding claim 11, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the array of electromagnetic emitters is positioned adjacent a head surface of the subject (Figs. 40, 41; [0201]; [0205]). Regarding claim 12, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the array of electromagnetic emitters is positioned adjacent a body surface of the subject (Figs. 40, 41; [0201]; [0205]). Regarding claims 13 and 14, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the increase in life span results from the electromagnetic waves balancing pro- and anti-inflammatory cytokines/immune mediators in a brain and/or body of the subject, from the electromagnetic waves inducing non-immune related actions in a brain and/or body of the subject ([0205]; the electromagnetic waves taught by Luttrull have all the parameters recited by claim 10 and are applied in the same manner as the present invention; thus, they would be able to provide such results). Regarding claim 17, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that applying electromagnetic treatment to the subject through the electromagnetic emitters comprises periodic treatments at predetermined intervals ([0205]). Regarding claim 19, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Arendash further discloses that the electromagnetic waves have an average SAR of 8.1 to 16 W/kg (Abstract; [0043]; claims 3, 9, 15, 20, 26). Arendash ‘997 teaches an average SAR of “about” 8 W/kg and also teaches that “about” does not limit the invention to a strict numerical interpretation and includes ranges of the relevant parameter. Further, it has been found that “about 1-5%” renders obvious a claim of “more than 5%,” as “about 1-5%” allows for amounts slightly above 5%. See MPEP 2144.05(I). Thus, “about 8 W/kg” is taken both by the teachings of Arendash ‘997 and by relevant case law to include amounts above 8 W/kg. Additionally, a prima facie case of obviousness can exist even where the claimed ranges do not overlap with the prior art but are merely close. See again MPEP 2144.05(I). Accordingly, the proposed combination is taken to render obvious the recited range as it reasonably includes at least 8.1 W/kg. There is no showing of criticality of the claimed range. Regarding claim 21, Luttrull discloses a method capable of increasing human life span (longevity) via electromagnetic treatment (Abstract; preventing neurodegenerative disease), the method comprising: positioning an array of electromagnetic emitters 124 proximal to a subject (Figs. 40, 41; [0200]-[0201]); generating, by an electromagnetic wave generator 132, electromagnetic waves having a predetermined set of parameters including a frequency of 1 megahertz (MHz) to 430 gigahertz (GHz), an average Specific Absorption Rate (SAR) of 2 watts per kilogram (W/kg), a pulse repetition rate of 1 to 300 hertz (Hz), or a duty cycle between 1% and 100% ([0202]-[0205]); applying the electromagnetic waves to the subject through the electromagnetic emitters to provide an increase of the life span of the subject ([0205]-[0206]), and treating the subject for at least one age-related disease selected from: all forms of dementia, all forms of cardiovascular disease, all forms of cancer, AIDS, traumatic brain injury, chronic traumatic encephalopathy, post-operative cognitive dysfunction, cognitive impairment after anesthesia, Rheumatoid Arthritis, bacterial or viral infections, Multiple Sclerosis, arterial hypertension, autoimmune diseases, all forms of depression and anxiety, cognitive impairment in depression, allergy, asthma, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, osteoarthritis, atherosclerosis, diabetes, COPD, chronic kidney disease, or metabolic syndrome ([0003]; [0059]; [0106]-[0107]; [0195]-[0196]; [0198]; [0290]; [0293]). Luttrull fails to expressly disclose an average SAR of 2.1 to 16 W/kg. Luttrull arguably renders this obvious, in light of its disclosure of 2.0 W/kg, as a prima facie case of obviousness can exist where the claimed ranges do not overlap with the prior art but are merely close. See MPEP 2144.05(I). However, for sake of completeness, Arendash ‘997 discloses a similar method (Abstract) that provides electromagnetic waves with a SAR of up to about 8 W/kg in order to enhance cognition and treat the underlying neurological disorder (Abstract; [0016]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Luttrull with the SAR taught by Arendash ‘997 in order to enhance cognition and treat the underlying neurological disorder. Regarding claim 22, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the array of electromagnetic emitters is positioned adjacent a head surface of the subject (Figs. 40, 41; [0201]; [0205]). Regarding claim 23, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the array of electromagnetic emitters is positioned adjacent a body surface of the subject (Figs. 40, 41; [0201]; [0205]). Regarding claims 24 and 25, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that the increase in life span results from the electromagnetic waves balancing pro- and anti-inflammatory cytokines/immune mediators in a brain and/or body of the subject, from the electromagnetic waves inducing non-immune related actions in a brain and/or body of the subject ([0205]; the electromagnetic waves taught by Luttrull have all the parameters recited by claim 10 and are applied in the same manner as the present invention; thus, they would be able to provide such results). Regarding claim 26, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Luttrull further discloses that applying electromagnetic treatment to the subject through the electromagnetic emitters comprises periodic treatments at predetermined intervals ([0205]). Regarding claim 27, the combination of Luttrull and Arendash ‘997 discloses the invention as claimed, see rejection supra, and Arendash further discloses that the electromagnetic waves have an average SAR of 8.1 to 16 W/kg (Abstract; [0043]; claims 3, 9, 15, 20, 26). Arendash ‘997 teaches an average SAR of “about” 8 W/kg and also teaches that “about” does not limit the invention to a strict numerical interpretation and includes ranges of the relevant parameter. Further, it has been found that “about 1-5%” renders obvious a claim of “more than 5%,” as “about 1-5%” allows for amounts slightly above 5%. See MPEP 2144.05(I). Thus, “about 8 W/kg” is taken both by the teachings of Arendash ‘997 and by relevant case law to include amounts above 8 W/kg. Additionally, a prima facie case of obviousness can exist even where the claimed ranges do not overlap with the prior art but are merely close. See again MPEP 2144.05(I). Accordingly, the proposed combination is taken to render obvious the recited range as it reasonably includes at least 8.1 W/kg. There is no showing of criticality of the claimed range. Response to Arguments Applicant’s arguments with respect to the rejection of claims 15, 16, and 18 under 35 U.S.C. 112(a) have been fully considered and are persuasive in light of the amendments. The rejections have been withdrawn. Applicant's arguments with respect to the rejections under 35 U.S.C. 103 have been fully considered but they are not persuasive. Applicant argues that the independent claims now substantially include the allowable subject matter from now-canceled claim 15. The examiner disagrees. The independent claims now recite treating the subject for at least one of the broad and lengthy list of age-related diseases, rather than that the increase in life span results via reduced occurrence/severity of the broad and lengthy list of age-related diseases. The latter is what was not taught by the prior art of record; however, as noted previously, it was also not taught by the specification as-filed. The proposed combination (as well as Arendash) does indeed teach treating the subject for at least one of the broad and lengthy list of age-related diseases, as detailed supra. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to THADDEUS B COX whose telephone number is (571)270-5132. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason M. Sims can be reached at (571)272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /THADDEUS B COX/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 2 earlier events
Jan 05, 2026
Non-Final Rejection mailed — §102, §103
Apr 01, 2026
Response Filed
May 01, 2026
Final Rejection mailed — §102, §103
Jun 22, 2026
Response after Non-Final Action
Jul 30, 2026
Response after Non-Final Action
Sep 01, 2026
Request for Continued Examination
Sep 03, 2026
Response after Non-Final Action
Oct 21, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773570
EEG BASED MULTI-FREQUENCY STIMULATION
3y 3m to grant Granted Oct 27, 2026
Patent 12773160
TUMESCENSE MONITORING SYSTEM FOR DIAGNOSING ERECTILE DYSFUNCTION AND METHODS OF USE
3y 7m to grant Granted Oct 27, 2026
Patent 12773519
SYSTEM AND METHOD FOR SOOTHING INFANTS
3y 3m to grant Granted Oct 27, 2026
Patent 12766070
PARTNER TOY FOR MASSAGING A FIRST AND A SECOND PERSON
4y 5m to grant Granted Oct 20, 2026
Patent 12766288
METHODS AND SYSTEMS OF PAVLOVIAN SLEEP INDUCTION
4y 4m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
96%
With Interview (+18.8%)
2y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1186 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month